[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

MOLECULAR TARGETS FOR THERAPY

The ENL YEATS epigenetic reader domain critically links MLL-ENL to leukemic stem cell frequency in t(11;19) Leukemia

Leukemia volume 37, pages 190–201 (2023)Cite this article

Subjects

Abstract

MLL (KMT2a) translocations are found in ~10% of acute leukemia patients, giving rise to oncogenic MLL-fusion proteins. A common MLL translocation partner is ENL and associated with a poor prognosis in t(11;19) patients. ENL contains a highly conserved N-terminal YEATS domain that binds acetylated histones and interacts with the PAF1c, an epigenetic regulator protein complex essential for MLL-fusion leukemogenesis. Recently, wild-type ENL, and specifically the YEATS domain, was shown to be essential for leukemic cell growth. However, the inclusion and importance of the YEATS domain in MLL-ENL-mediated leukemogenesis remains unexplored. We found the YEATS domain is retained in 84.1% of MLL-ENL patients and crucial for MLL-ENL-mediated leukemogenesis in mouse models. Mechanistically, deletion of the YEATS domain impaired MLL-ENL fusion protein binding and decreased expression of pro-leukemic genes like Eya1 and Meis1. Point mutations that disrupt YEATS domain binding to acetylated histones decreased stem cell frequency and increased MLL-ENL-mediated leukemia latency. Therapeutically, YEATS containing MLL-ENL leukemic cells display increased sensitivity to the YEATS inhibitor SGC-iMLLT compared to control AML cells. Our results demonstrate that the YEATS domain is important for MLL-ENL fusion protein-mediated leukemogenesis and exposes an “Achilles heel” that may be therapeutically targeted for treating t(11;19) patients.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: ENL breakpoint locations in t(11;19) patients.
Fig. 2: The ENL YEATS domain and downstream sequence is required for MLL-ENL-mediated leukemogenesis.
Fig. 3: YEATS domain mutations impact H3Kac binding.
Fig. 4: Disruption of the YEATS domain epigenetic reader function impacts MLL-ENL leukemic stem cell frequency.
Fig. 5: Transcriptomic changes associated with MLL-ENLΔYEATS cells.
Fig. 6: YEATS domain of ENL is required for epigenetic regulation of Eya1.
Fig. 7: MLL-ENL cells display increased sensitivity to SGC-iMLLT.
Fig. 8: The YEATS domain impacts MLL-ENL fusion protein localization.

Similar content being viewed by others

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request and in the Gene Expression Omnibus (GEO) repository: GSE211523.

References

  1. Balgobind BV, Zwaan CM, Pieters R, Van den Heuvel-Eibrink MM. The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia. Leukemia. 2011;25:1239–48.

    Article  CAS  Google Scholar 

  2. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007;7:823–33.

    Article  CAS  Google Scholar 

  3. Tkachuk DC, Kohler S, Cleary ML. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell. 1992;71:691–700.

    Article  CAS  Google Scholar 

  4. Winters AC, Bernt KM. MLL-rearranged leukemias-an update on science and clinical approaches. Front Pediatr. 2017;5:4.

    Article  Google Scholar 

  5. Meyer C, Kowarz E, Hofmann J, Renneville A, Zuna J, Trka J, et al. New insights to the MLL recombinome of acute leukemias. Leukemia. 2009;23:1490–9.

    Article  CAS  Google Scholar 

  6. Milne TA, Briggs SD, Brock HW, Martin ME, Gibbs D, Allis CD, et al. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell. 2002;10:1107–17.

    Article  CAS  Google Scholar 

  7. Meyer C, Burmeister T, Groger D, Tsaur G, Fechina L, Renneville A, et al. The MLL recombinome of acute leukemias in 2017. Leukemia. 2018;32:273–84.

    Article  CAS  Google Scholar 

  8. Lin C, Smith ER, Takahashi H, Lai KC, Martin-Brown S, Florens L, et al. AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol Cell. 2010;37:429–37.

    Article  CAS  Google Scholar 

  9. Mueller D, Bach C, Zeisig D, Garcia-Cuellar MP, Monroe S, Sreekumar A, et al. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood. 2007;110:4445–54.

    Article  CAS  Google Scholar 

  10. Yokoyama A, Lin M, Naresh A, Kitabayashi I, Cleary ML. A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell. 2010;17:198–212.

    Article  CAS  Google Scholar 

  11. Bitoun E, Oliver PL, Davies KE. The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. Hum Mol Genet. 2007;16:92–106.

    Article  CAS  Google Scholar 

  12. Marshall NF, Peng J, Xie Z, Price DH. Control of RNA polymerase II elongation potential by a novel carboxyl-terminal domain kinase. J Biol Chem. 1996;271:27176–83.

    Article  CAS  Google Scholar 

  13. Okada Y, Feng Q, Lin Y, Jiang Q, Li Y, Coffield VM, et al. hDOT1L links histone methylation to leukemogenesis. Cell. 2005;121:167–78.

    Article  CAS  Google Scholar 

  14. Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell. 2011;20:66–78.

    Article  CAS  Google Scholar 

  15. Mohan M, Herz HM, Takahashi YH, Lin C, Lai KC, Zhang Y, et al. Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom). Genes Dev. 2010;24:574–89.

    Article  CAS  Google Scholar 

  16. Okuda H, Stanojevic B, Kanai A, Kawamura T, Takahashi S, Matsui H, et al. Cooperative gene activation by AF4 and DOT1L drives MLL-rearranged leukemia. J Clin Investig. 2017;127:1918–31.

    Article  Google Scholar 

  17. Ayton PM, Cleary ML. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev. 2003;17:2298–307.

    Article  CAS  Google Scholar 

  18. Wong P, Iwasaki M, Somervaille TC, So CW, Cleary ML. Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. Genes Dev. 2007;21:2762–74.

    Article  CAS  Google Scholar 

  19. Zeisig BB, Milne T, Garcia-Cuellar MP, Schreiner S, Martin ME, Fuchs U, et al. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol Cell Biol. 2004;24:617–28.

    Article  CAS  Google Scholar 

  20. Chang MJ, Wu H, Achille NJ, Reisenauer MR, Chou CW, Zeleznik-Le NJ, et al. Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes. Cancer Res. 2010;70:10234–42.

    Article  CAS  Google Scholar 

  21. Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011;20:53–65.

    Article  CAS  Google Scholar 

  22. Du L, Grigsby SM, Yao A, Chang Y, Johnson G, Sun H, et al. Peptidomimetics for targeting protein-protein interactions between DOT1L and MLL oncofusion proteins AF9 and ENL. ACS Med Chem Lett. 2018;9:895–900.

    Article  CAS  Google Scholar 

  23. Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU, et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell. 2008;14:355–68.

    Article  CAS  Google Scholar 

  24. Grigsby SM, Friedman A, Chase J, Waas B, Ropa J, Serio J, et al. Elucidating the importance of DOT1L recruitment in MLL-AF9 leukemia and hematopoiesis. Cancers. 2021;13:642.

  25. Stein EM, Garcia-Manero G, Rizzieri DA, Tibes R, Berdeja JG, Savona MR, et al. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood 2018;131:2661–9.

    Article  CAS  Google Scholar 

  26. Christott T, Bennett J, Coxon C, Monteiro O, Giroud C, Beke V, et al. Discovery of a Selective Inhibitor for the YEATS Domains of ENL/AF9. SLAS Discov. 2019;24:133–41.

    Article  CAS  Google Scholar 

  27. Erb MA, Scott TG, Li BE, Xie H, Paulk J, Seo HS, et al. Transcription control by the ENL YEATS domain in acute leukaemia. Nature. 2017;543:270–4.

    Article  CAS  Google Scholar 

  28. Wan L, Wen H, Li Y, Lyu J, Xi Y, Hoshii T, et al. ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia. Nature. 2017;543:265–9.

    Article  CAS  Google Scholar 

  29. Calvanese V, Nguyen AT, Bolan TJ, Vavilina A, Su T, Lee LK, et al. MLLT3 governs human haematopoietic stem-cell self-renewal and engraftment. Nature. 2019;576:281–6.

    Article  CAS  Google Scholar 

  30. Srinivasan RS, Nesbit JB, Marrero L, Erfurth F, LaRussa VF, Hemenway CS. The synthetic peptide PFWT disrupts AF4-AF9 protein complexes and induces apoptosis in t(4;11) leukemia cells. Leukemia. 2004;18:1364–72.

    Article  CAS  Google Scholar 

  31. Shen C, Jo SY, Liao C, Hess JL, Nikolovska-Coleska Z. Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins. J Biol Chem. 2013;288:30585–96.

    Article  CAS  Google Scholar 

  32. Kuntimaddi A, Achille NJ, Thorpe J, Lokken AA, Singh R, Hemenway CS, et al. Degree of recruitment of DOT1L to MLL-AF9 defines level of H3K79 Di- and tri-methylation on target genes and transformation potential. Cell Rep. 2015;11:808–20.

    Article  CAS  Google Scholar 

  33. Zeisig DT, Bittner CB, Zeisig BB, Garcia-Cuellar MP, Hess JL, Slany RK. The eleven-nineteen-leukemia protein ENL connects nuclear MLL fusion partners with chromatin. Oncogene. 2005;24:5525–32.

    Article  CAS  Google Scholar 

  34. He N, Chan CK, Sobhian B, Chou S, Xue Y, Liu M, et al. Human Polymerase-Associated Factor complex (PAFc) connects the Super Elongation Complex (SEC) to RNA polymerase II on chromatin. Proc Natl Acad Sci USA. 2011;108:E636–45.

    Article  CAS  Google Scholar 

  35. Leach BI, Kuntimaddi A, Schmidt CR, Cierpicki T, Johnson SA, Bushweller JH. Leukemia fusion target AF9 is an intrinsically disordered transcriptional regulator that recruits multiple partners via coupled folding and binding. Structure 2013;21:176–83.

    Article  CAS  Google Scholar 

  36. Slany RK, Lavau C, Cleary ML. The oncogenic capacity of HRX-ENL requires the transcriptional transactivation activity of ENL and the DNA binding motifs of HRX. Mol Cell Biol. 1998;18:122–9.

    Article  CAS  Google Scholar 

  37. Li Y, Wen H, Xi Y, Tanaka K, Wang H, Peng D, et al. AF9 YEATS domain links histone acetylation to DOT1L-mediated H3K79 methylation. Cell. 2014;159:558–71.

    Article  CAS  Google Scholar 

  38. Perlman EJ, Gadd S, Arold ST, Radhakrishnan A, Gerhard DS, Jennings L, et al. MLLT1 YEATS domain mutations in clinically distinctive Favourable Histology Wilms tumours. Nat Commun. 2015;6:10013.

    Article  CAS  Google Scholar 

  39. Wan L, Chong S, Xuan F, Liang A, Cui X, Gates L, et al. Impaired cell fate through gain-of-function mutations in a chromatin reader. Nature. 2020;577:121–6.

    Article  CAS  Google Scholar 

  40. Tomson BN, Arndt KM. The many roles of the conserved eukaryotic Paf1 complex in regulating transcription, histone modifications, and disease states. Biochim Biophys Acta. 2012;1829:116–26.

  41. Milne TA, Kim J, Wang GG, Stadler SC, Basrur V, Whitcomb SJ, et al. Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis. Mol Cell. 2010;38:853–63.

    Article  CAS  Google Scholar 

  42. Muntean AG, Chen W, Jones M, Granowicz EM, Maillard I, Hess JL. MLL fusion protein-driven AML is selectively inhibited by targeted disruption of the MLL-PAFc interaction. Blood. 2013;122:1914–22.

    Article  CAS  Google Scholar 

  43. Muntean AG, Tan J, Sitwala K, Huang Y, Bronstein J, Connelly JA, et al. The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis. Cancer Cell. 2010;17:609–21.

    Article  CAS  Google Scholar 

  44. Li X, Li XM, Jiang Y, Liu Z, Cui Y, Fung KY, et al. Structure-guided development of YEATS domain inhibitors by targeting pi-pi-pi stacking. Nat Chem Biol. 2018;14:1140–9.

    Article  CAS  Google Scholar 

  45. Moustakim M, Christott T, Monteiro OP, Bennett J, Giroud C, Ward J, et al. Discovery of an MLLT1/3 YEATS domain chemical probe. Angew Chem Int Ed Engl. 2018;57:16302–7.

    Article  CAS  Google Scholar 

  46. Liu Y, Li Q, Alikarami F, Barrett DR, Mahdavi L, Li H, et al. Small-molecule inhibition of the acyl-lysine reader ENL as a strategy against acute myeloid leukemia. Cancer Discov. 2022;12:2684–709.

  47. Zhao D, Li Y, Xiong X, Chen Z, Li H. YEATS Domain-a histone acylation reader in health and disease. J Mol Biol. 2017;429:1994–2002.

    Article  CAS  Google Scholar 

  48. Rubnitz JE, Behm FG, Curcio-Brint AM, Pinheiro RP, Carroll AJ, Raimondi SC, et al. Molecular analysis of t(11;19) breakpoints in childhood acute leukemias. Blood. 1996;87:4804–8.

    Article  CAS  Google Scholar 

  49. Fu JF, Liang DC, Shih LY. Analysis of acute leukemias with MLL/ENL fusion transcripts: identification of two novel breakpoints in ENL. Am J Clin Pathol. 2007;127:24–30.

    Article  CAS  Google Scholar 

  50. Hetzner K, Garcia-Cuellar MP, Buttner C, Slany RK. The interaction of ENL with PAF1 mitigates polycomb silencing and facilitates murine leukemogenesis. Blood. 2018;131:662–73.

    Article  CAS  Google Scholar 

  51. Laslo P, Spooner CJ, Warmflash A, Lancki DW, Lee HJ, Sciammas R, et al. Multilineage transcriptional priming and determination of alternate hematopoietic cell fates. Cell. 2006;126:755–66.

    Article  CAS  Google Scholar 

  52. Garcia-Cuellar MP, Buttner C, Bartenhagen C, Dugas M, Slany RK. Leukemogenic MLL-ENL fusions induce alternative chromatin states to drive a functionally dichotomous group of target genes. Cell Rep. 2016;15:310–22.

    Article  CAS  Google Scholar 

  53. Wilkinson AC, Ballabio E, Geng H, North P, Tapia M, Kerry J, et al. RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction. Cell Rep. 2013;3:116–27.

    Article  CAS  Google Scholar 

  54. Wang QF, Wu G, Mi S, He F, Wu J, Dong J, et al. MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome. Blood. 2011;117:6895–905.

    Article  CAS  Google Scholar 

  55. Andersson AK, Ma J, Wang J, Chen X, Gedman AL, Dang J, et al. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat Genet. 2015;47:330–7.

    Article  CAS  Google Scholar 

  56. Guo C, Che Z, Yue J, Xie P, Hao S, Xie W, et al. ENL initiates multivalent phase separation of the super elongation complex (SEC) in controlling rapid transcriptional activation. Sci Adv. 2020;6:eaay4858.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Drs. Tomek Cierpicki, Jolanta Grembecka, Yali Dou and Mark Chiang for helpful discussion and Dr. Lili Zhao for statistical help. We thank Dr. Michael Cleary for MLL-ENL expression plasmids and Dr. Akihiko Yokoyama for HB1119 cells. This work was supported by NIH grants: MCubed (ZNC, AGM), Michigan Drug Discovery (ZNC), R01-HL-136420 (AGM), B+ Foundation (AGM) and P30CA046592 (University of Michigan Flow Cytometry Core).

Author information

Author notes

  1. These authors contributed equally: Hsiangyu Hu, Nirmalya Saha.

Authors and Affiliations

  1. Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA

    Hsiangyu Hu, Nirmalya Saha, Yuting Yang, Ejaz Ahmad, Lauren Lachowski, Uttar Shrestha, Vidhya Premkumar, Lili Chen, Blaine Teahan, Sierrah Grigsby, Zaneta Nikolovska-Coleska & Andrew G. Muntean

  2. Department of Microbiology and Immunology, Indiana University School of Medicine, 950 West Walnut Street, R2-302, Indianapolis, IN, 46202-5181, USA

    James Ropa

  3. Institute of Pharmaceutical Biology / Diagnostic Center of Acute Leukemia, University of Frankfurt, Frankfurt/Main, Germany

    Rolf Marschalek

Authors
  1. Hsiangyu Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nirmalya Saha
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuting Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ejaz Ahmad
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lauren Lachowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Uttar Shrestha
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Vidhya Premkumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. James Ropa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Lili Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Blaine Teahan
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Sierrah Grigsby
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Rolf Marschalek
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Zaneta Nikolovska-Coleska
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Andrew G. Muntean
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

HH, NS, ZNC and AGM designed the experiments. All authors participated in conducting experiments and collecting or analyzing the data. YY conducted cloning, expression and purification of recombinant proteins; EA conducted FP and BLI binding assays; US performed synthesis of the fluorescent-labeled inhibitor. RM provided chromosomal breakpoint data and analysis. HH, ZNC and AGM wrote the manuscript. The project was overseen by AGM.

Corresponding author

Correspondence to Andrew G. Muntean.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hu, H., Saha, N., Yang, Y. et al. The ENL YEATS epigenetic reader domain critically links MLL-ENL to leukemic stem cell frequency in t(11;19) Leukemia. Leukemia 37, 190–201 (2023). https://doi.org/10.1038/s41375-022-01765-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-022-01765-0

This article is cited by

Search

Advanced search

Quick links